Peptide inhibitors of HIV entry

Details Peptide inhibitors of HIV entry Peptide inhibitors of HIV entry

2000-09-22

2004-06-08

Housel, James (Department: 1648)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C424S188100, C424S208100

Reexamination Certificate

active

06747126

ABSTRACT:

BACKGROUND OF THE INVENTION
HIV is the virus that is responsible for the worldwide AIDS epidemic. The initial stages of HIV infection involve the fusion of viral membrane with the target cell membrane, a process that injects the viral contents into the cellular cytoplasm. On the viral side, the molecular complex responsible for the fusion activity contains the surface protein gp 120 and the transmembrane protein gp41. It is the current hypothesis that gp120 interacts with the proteins CD4 and coreceptor on the target cell, resulting in a conformational change that causes gp41 to insert its amino terminus (fusion peptide region) into the target cell membrane. This structural rearrangement promotes the fusion of virus and cellular membranes through a poorly understood mechanism.
SUMMARY OF THE INVENTION
Described herein are chimeric peptides comprising a soluble trimeric coiled-coil and all or a portion of the N-peptide region of HIV gp41. These molecules are stable, trimeric coiled-coils that inhibit HIV entry into cells, such as human cells. Such peptides can be further assessed to demonstrate their ability to serve as potent anti-HIV therapeutic molecules and thus, as therapeutic molecules or drugs.


REFERENCES:
patent: 5444044 (1995-08-01), Jiang et al.
patent: 5464933 (1995-11-01), Bolognesi et al.
patent: 5656480 (1997-08-01), Wild et al.
patent: 5840843 (1998-11-01), Jiang et al.
patent: 6150088 (2000-11-01), Chan et al.
patent: 6506554 (2003-01-01), Chan et al.
patent: 2002/0077284 (2002-06-01), Eckert et al.
patent: 2003/0082525 (2003-05-01), Root et al.
patent: 2003/0099935 (2003-05-01), Chan et al.
patent: WO 94/02505 (1994-02-01), None
patent: WO 96/40191 (1996-12-01), None
patent: WO 98/32848 (1998-07-01), None
patent: WO 00/06599 (2000-02-01), None
patent: WO 00/40616 (2000-07-01), None
patent: WO 01/03723 (2001-01-01), None
patent: WO 01/44286 (2001-06-01), None
Baum, Rudy, “Viral-cell Fusion Targeted for Drug Development,”C&EN(1996).
Blacklow, Stephen C., et al., “A Trimeric Subdomain of the Simian Immunodeficiency Virus Envelope Glycoprotein,”Biochemistry, 34(46):14955-14962 (1995).
Blake, James and Li, Choh Hao, “Adrenocorticotropin. 47. Synthesis and Biological Activity of Adrenocorticotropic Peptides Modified at the Tryptophan Position,”J. Medicinal Chem.18(4):423-426 (1975).
Borchardt, Allen et al., “Small Molecule-dependent genetic selection in stochastic nanodroplets as a means of detecting protein-ligand interactions on a large scale,”Chem.&Biol.4(12):961-968 (1997).
Bullough, Per A. et al., “Structure of influenza haemagglutinin at the pH of membrane fusion,”Nature371:37-43 (1994).
Caffrey, Michael et al., “Three-dimensional solution structure of the 44kDa ectodomain of SIV gp41,”EMBO J.17(16):4572-4584 (1998).
Cao, Jie et al., “Effects of Amino Acid Changes in the Extracellular Domain of the Human Immunodeficiency Virus Type 1 gp41 Envelope Glycoprotein,”J. Virology67(5):2747-2755 (1993).
Chabala, John C., “Solid-phase combinatorial chemistry and novel tagging methods for identifying leads,”Curr. Opin. Biotech.6:632-639 (1995).
Chakrabartty, Avijit et al., “Aromatic Side-Chain Contribution to Far-Ultraviolet Circular Dichroism of Helical Peptides and Its Effect on Measurement of Helix Propensities,”Biochemistry32:5560-5565 (1993).
Chambers, Philip, et al., “Heptad Repeat Sequences are Located Adjacent to Hydrophobic Regions in Several Types of Virus Fusion Glycoproteins,”Journal of General Virology, 71:3075-3080 (1990).
Chan, David D., et al., “Evidence that a Prominent Cavity in the Coiled Coil of HIV Type I gp41 is an Attractive Drug Target,”Proc. Natl. Acad. Sci. USA 95:15613-15617 (1998).
Chan, David C., et al., “Core Structure of gp41 from the HIV Envelope Glycoprotein,”Cell 89:263-273 (1997).
Chan, David C. and Kim, Peter A., “HIV Entry and Its Inhibition,”Cell93:681-684 (1998).
Chen, Yee-Hsiung et al., “Determination of the Helix and &bgr; Form of Proteins in Aqueous Solution by Circular Dichroism,”Biochemistry13(16):3350-3359 (1974).
Chen, Benjamin K. et al., “Distinct Modes of Human Immunodeficiency Virus Type 1 Proviral Latency Revealed by Superinfection of Nonproductively Infected Cell Lines with Recombinant Luciferase-Encoding Viruses,”J. Virology68(2):654-660 (1994).
Chen, Charlie L. et al., “One Bead-One Compound Combinatorial Peptide Library: Different Types of Screening,”Methods in Enzymology267:211-219 (1996).
Chen, Chin-Ho et al., “A Molecular Clasp in the Human Immunodeficiency Virus (HIV) Type 1 TM Protein Determines the Anti-HIV Activity of gp41 Derivatives:Implication for Viral Fusion,”J. Virology69(6):3771-3777 (1995).
Cole, James L. and Garsky, Victor M., “Thermodynamics of Peptide Inhibitor Binding to HIV-1 gp41,”Biochemistry40:5633-5641 (2001).
Delwart, Eric L., et al., “Retroviral Envelope Glycoproteins Contain a “Leucine Zipper”-like Repeat,”AIDS Research and Human Retroviruses, 6(6):703-706 (1990).
Doering Don S. and Matsudaira, Paul, “Cysteine Scanning Mutagenesis at 40 of 76 Positions in Villin Headpiece Maps the F-Actin Binding Site and Structural Features of the Domain,”Biochemistry35:12677-12685 (1996).
Dutch, Rebecca Ellis et al., “Paramyxovirus Fusion Protein: Characterization of the Core Trimer, a Rod-Shaped Complex with Helices in Anti-Parallel Orientation,”Virology254:147-159 (1999).
Eckert, Debra M., et al., “Inhibiting HIV-1 Entry: Discovery of D-Peptide Inhibitors that Target the gp41 Coiled-Coil Pocket,”Cell 99:103-115 (1999).
Eckert, Debra M. et al., “Crystal Structure of GCN4-plQl, a Trimeric Coiled Coil with Buried Polar Residues,”J. Mol. Biol.284:859-865 (1998).
Eckhart, Leopold et al., “Immunogenic Presentation of a Conserved gp41 Epitope of Human Immunodeficiency Virus Type I on Recombinant Surface Antigen of Hepatitis B Virus,”J. Gen. Virol. 77:2001-2008 (1996).
Edelhoch, Harold, “Spectroscopic Determination of Tryptophan and Tyrosine in Proteins,”Biochemistry6: (7) :1948-1954 (1967).
Fass, Deborah et al., “Retrovirus envelop domain at 1.7 Åresolution,”Nature Structural Biology3(5):465-469 (1996).
Fass, Deobrah and Kim, Peter S., “Dissection of a retrovirus envelope protein reveals structural similarity to influenza hemagglutinin,” Current Biology 5(12):1-7 (1995).
Furuta et al., “Capture of an early fusion-active conformation of HIV-1 gp41,”Nature Structural Biology5(4):276-279 (1998).
Gallaher, William R., et al., “A General Model for the Transmembrane Proteins of HIV and Other Retroviruses,”Aids Research and Human Retroviruses, 5(4):431-440 (1989).
Harbury, Pehr B. et al., “Repacking protein cores with backbone freedom:Structure prediction for coiled coils,”Proc. Natl. Acad. Sci, USA92:8408-8412 (1995).
Harbury, Pehr B. et al., “Crystal structure of an isoleucine-zipper trimer,”Nature371:80-83 (1994).
Hirsch, Vanessa M. and Johnson, Philip R., “Pathogenic diversity of simian immunodeficiency viruses,”Virus Research32:183-206 (1994).
Hooft, Rob W.W. and Vriend, Gert, “Errors in protein structures,”Nature381:272 (1996).
Jiang, Shibo et al., “A Conformation-Specific Monoclonal Antibody Reacting with Fusion-Active gp41 from the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein,”J. of Virology72 (12):10213-10271 (1998).
Jiang, S. et al., “A screening assay for antiviral compounds targeted to the HIV-1 gp41 core structure using a conformation-specific monoclonal antibody,”J. Virol. Methods80:85-96 (1999).
Jiang, Shibo et al., “HIV-1 inhibition by a peptide,”Nature365:113 (1993).
Jones, T.A. et al., “Improved Methods for Builidng Protein Models in Electron Density Maps and the Location of Errors in these Models,”Acta Cryst.A47:110-119 (1991).
Judice, J. Kevin et al., “Inhibition of HIV type 1 infectivity by constrained &agr;-helical peptides:Implications for the viral fusion mechanism,”Proc. Natl. Acad. Sci. USA94:13426-13430 (1997).
Kilby, J. Michael et al., “Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry,”Nature Medicine4(11):1302-1307 (1998).
Kliger, Yossef et al., “Mode of Action of an Antiviral Peptide from HIV-1,”J. Biol. Chem

Affiliated with

Also associated with

Rating

Peptide inhibitors of HIV entry does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide inhibitors of HIV entry, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide inhibitors of HIV entry will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3359925